Stragen Pharma Group acquired by ArchiMed. The advisors
Private equity healthcare fund ArchiMed announced the acquisition of Stragen Pharma from its founder and several shareholders, through its EUR 1 billion MED Platform I fund.
The advisors
Walder Wyss acted as legal counsel to Stragen Pharma and its shareholders in the transaction, with a team led by Fouad G. Sayegh (partner, tax, pictured above) and Patrick W. Vogel (partner, corporate/ m&a) and included Yacine Rezki (associate, tax), Alexander Sorton (associate, corporate/m&a), Hugh Reeves (managing associate, ip) and Camille Tistounet (trainee lawyer).
Homburger acted as Swiss legal counsel to ArchiMed. The Homburger team was led by partner Frank Gerhard (pictured left), and comprised lead associate Sarah Chevalley, associate Léonard Aeschlimann Perales and junior associate Alessandra Dumitru (all corporate / m&a), as well as counsel Peter Müller (tax).
Stragen Pharma was founded in 1990 and is based near Geneva, Switzerland. It is a developer of complex generic drugs for the treatment of patients with life-threatening conditions that require comprehensive care and monitoring, usually in intensive care units. Stragen sales of some EUR 70 million in 2020 are growing at a double-digit annual pace. Stragen’s 40 different products are sold in over 60 countries around the world, with a strong European focus.
